Efficacy of second-line chemotherapy in advanced CCA with FGFR2 fusions

FGFR2 Inhibitors in Advanced CholangiocarcinomaПодробнее

PROOF: infigratinib as first-line therapy in patients with advanced CCAПодробнее

PROOF 301: infigratinib in advanced CCAПодробнее

[HR] The talk about systemic therapy for advanced cholangiocarcinoma from Hepatoma ResearchПодробнее

Webinar: Targeting the FGFR pathway: Infigratinib in cholangiocarcinomaПодробнее

2018 Cholangiocarcinoma Foundation Annual Conference #10 - Day 2 - FGFR SignalingПодробнее

FIGHT-202: pemigatinib for FGFR2 altered CCAПодробнее

Advanced Cholangiocarcinoma: FGFR2 Inhibitors vs ChemoПодробнее

Natural history of patients with advanced CCA with FGFR2 gene alterations or wild-type FGFR2Подробнее

PROOF 301: infigratinib vs. gem/cis in patients with CCA with an FGFR2 gene fusion/rearrangementПодробнее

FIGHT-202: pemigatinib in CCAПодробнее

Targeted therapies for cholangiocarcinoma in the second line settingПодробнее

AC22 - Explore Signaling Pathways and Combination Therapy in FGFR2-activated CholangiocarcinomaПодробнее

Final results from FIGHT-202: pemigatinib for patients with FGFR-mutated advanced cholangiocarcinomaПодробнее

FGFR Inhibitors in Development for CCAПодробнее

ICRN/ENS-CCA Webinar: "Challenges of Designing Immune Trials in the Second Line with Review of Data"Подробнее

Therapeutic Management of Biliary Cancers: Integrating Precision Medicine With Targeted StrategiesПодробнее

Webinar: TT-00420 TreatmentПодробнее

Discover how the FGFR2 gene influences cell behaviour and its link to cancer when mutated. #FGFR2Подробнее